NCT03330106View on ClinicalTrials.gov

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

January 7, 2019

Study Completion Date

June 21, 2021

Conditions
Advanced Solid Neoplasm
Interventions
DRUG

Pevonedistat

Pevonedistat intravenous infusion.

DRUG

Docetaxel

Docetaxel intravenous infusion.

DRUG

Carboplatin

Carboplatin intravenous infusion.

DRUG

Paclitaxel

Paclitaxel intravenous infusion.

Trial Locations (8)

10467

Montefiore Medical Center, The Bronx

22031

Virginia Cancer Specialists, Fairfax

23801

University of Oklahoma Health Sciences Center, Oklahoma City

33612

Moffitt Cancer Center, Tampa

44106

Case Western Reserve University, Cleveland

48202

Henry Ford Hospital, Detroit

75231

Mary Crowley Medical Research, Dallas

90403

Sarcoma Oncology Center, Santa Monica

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY